Cosentyx is a medication that contains secukinumab, a human monoclonal antibody that helps reduce inflammation in the body. According to Drugs.com, Cosentyx falls under Pregnancy Category B, which means that animal reproduction studies have not demonstrated a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women [3].

While there is limited information on the effects of Cosentyx on pregnancy, a study published in the Journal of Dermatological Treatment reported on 11 women who had received Cosentyx treatment during pregnancy. The study found that the medication did not appear to increase the risk of adverse outcomes such as preterm birth, stillbirth, or congenital anomalies [2]. However, the sample size was small, and more research is needed to confirm these findings.

It is recommended that women who are pregnant or planning to become pregnant discuss the potential risks and benefits of taking Cosentyx with their healthcare provider. The decision to continue or discontinue the medication during pregnancy should be made on a case-by-case basis, taking into consideration the severity of the underlying condition and the potential risks to the mother and fetus [3].

In conclusion, while there is limited information on the safety of Cosentyx during pregnancy, it falls under Pregnancy Category B, and a small study has not found an increased risk of adverse outcomes. Women who are pregnant or planning to become pregnant should discuss the potential risks and benefits of taking Cosentyx with their healthcare provider and make an informed decision based on their individual circumstances [2][3].

Sources:
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874874/
[3] https://www.drugs.com/pregnancy/secukinumab.html